Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.

[1]  H. Maegawa,et al.  Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) , 2020, Diabetes Therapy.

[2]  Maryam Rameshrad,et al.  An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning , 2020, Iranian journal of basic medical sciences.

[3]  R. Pratley,et al.  GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials , 2020, Frontiers in Endocrinology.

[4]  K. Khunti,et al.  Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis , 2020, Diabetes, obesity & metabolism.

[5]  Mohammad Hossein Sharifi,et al.  Adherence to Medication, Diet and Physical Activity and the Associated Factors Amongst Patients with Type 2 Diabetes , 2020, Diabetes Therapy.

[6]  Y. Iwamoto.  Vildagliptin , 2020, Reactions Weekly.

[7]  A. Avogaro,et al.  Effects of basal insulin on lipid profile compared to other classes of anti-hyperglycaemic agents in type 2 diabetic patients. , 2020, The Journal of clinical endocrinology and metabolism.

[8]  Joshua J. Neumiller,et al.  Oral Semaglutide , 2019, Clinical Diabetes.

[9]  B. Tomlinson,et al.  An evaluation of liraglutide including its efficacy and safety for the treatment of obesity , 2019, Expert opinion on pharmacotherapy.

[10]  W. Wongcharoen,et al.  Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study , 2019, British journal of clinical pharmacology.

[11]  J. Holst.  From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy , 2019, Front. Endocrinol..

[12]  A. Ceriello,et al.  The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice , 2019, Drugs.

[13]  J. Tack,et al.  Randomised clinical trial: the DPP‐4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon‐like peptide‐1 plasma levels in healthy volunteers , 2019, Alimentary pharmacology & therapeutics.

[14]  Maryam Rameshrad,et al.  Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning , 2019, DARU Journal of Pharmaceutical Sciences.

[15]  V. Preumont,et al.  Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients. , 2019, Diabetes & metabolic syndrome.

[16]  J. Martínez,et al.  Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial. , 2018, International journal of epidemiology.

[17]  Jennifer M. Trujillo,et al.  Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes , 2018, The Annals of pharmacotherapy.

[18]  S. Xu,et al.  Absorption, metabolism and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans , 2018, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  T. Vilsbøll,et al.  Glucagon-like peptide 1 in health and disease , 2018, Nature Reviews Endocrinology.

[20]  A. Bitton,et al.  Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study , 2018, British Medical Journal.

[21]  A. Scheen.  The safety of gliptins : updated data in 2018 , 2018, Expert opinion on drug safety.

[22]  S. Doggrell.  Sgemaglutide in type 2 diabetes – is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? , 2018, Expert opinion on drug metabolism & toxicology.

[23]  W. Polonsky,et al.  Real‐world weight change among patients treated with glucagon‐like peptide‐1 receptor agonist, dipeptidyl peptidase‐4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence , 2017, Obesity science & practice.

[24]  Young In Park,et al.  Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. , 2017, American health & drug benefits.

[25]  G. Finlayson,et al.  Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity , 2017, Diabetes, obesity & metabolism.

[26]  P. Christiansen,et al.  Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? , 2017, Acta Diabetologica.

[27]  Virginia Savin,et al.  Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. , 2017, American journal of physiology. Renal physiology.

[28]  J. Marrugat,et al.  Validation of the Regicor Short Physical Activity Questionnaire for the Adult Population , 2017, PloS one.

[29]  G. Li Volti,et al.  Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study , 2016, Cardiovascular Diabetology.

[30]  M. Carrington,et al.  A metabolic syndrome severity score: A tool to quantify cardio-metabolic risk factors. , 2016, Preventive medicine.

[31]  B. Tomlinson,et al.  An overview of new GLP-1 receptor agonists for type 2 diabetes , 2016, Expert opinion on investigational drugs.

[32]  S. Madsbad.  Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists , 2015, Diabetes, obesity & metabolism.

[33]  K. McKeage.  Trelagliptin: First Global Approval , 2015, Drugs.

[34]  Yaping Tian,et al.  Comparisons of Different Metabolic Syndrome Definitions and Associations with Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Rural Chinese Population , 2015, PloS one.

[35]  B. Zinman,et al.  Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis , 2014, The Lancet.

[36]  S. Zhan,et al.  Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. , 2015, Clinical therapeutics.

[37]  Sang-Heon Cho,et al.  Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers , 2014, Drug design, development and therapy.

[38]  D. Giugliano,et al.  Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials , 2014, BMJ Open.

[39]  J. Doupis.  Linagliptin: from bench to bedside , 2014, Drug design, development and therapy.

[40]  B. Ahrén.  Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. , 2014, World journal of diabetes.

[41]  A. Tsapas,et al.  Safety of dipeptidyl peptidase 4 inhibitors: a perspective review , 2014, Therapeutic advances in drug safety.

[42]  H. Yim,et al.  Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry , 2013, Archives of pharmacal research.

[43]  S. Warrington,et al.  Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[44]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[45]  E. Deeks.  Linagliptin: a review of its use in the management of type 2 diabetes mellitus. , 2012, Drugs.

[46]  C. Deacon,et al.  Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis , 2012, Diabetes, obesity & metabolism.

[47]  A. Garber,et al.  Liraglutide in oral antidiabetic drug combination therapy , 2012, Diabetes, obesity & metabolism.

[48]  S. Bloom,et al.  Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity , 2012, Gut and liver.

[49]  A. Corsini,et al.  Pharmacology of Dipeptidyl Peptidase-4 Inhibitors , 2011, Drugs.

[50]  Sohita Dhillon,et al.  Saxagliptin , 2012, Drugs.

[51]  D. Drucker,et al.  Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology , 2011, Diabetologia.

[52]  A. Avogaro,et al.  The metabolic syndrome influences the response to incretin-based therapies , 2011, Acta Diabetologica.

[53]  Henrik Vestergaard,et al.  Impaired regulation of the incretin effect in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[54]  J. Levy,et al.  The incretin pathway as a new therapeutic target for obesity. , 2010, Maturitas.

[55]  M. S. Lewis,et al.  Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. , 2010, The American journal of medicine.

[56]  D. Yabe,et al.  GIP and GLP‐1, the two incretin hormones: Similarities and differences , 2010, Journal of diabetes investigation.

[57]  M. Christensen,et al.  Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide? , 2010, Current diabetes reports.

[58]  Dolores Corella,et al.  Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain , 2010, British Journal of Nutrition.

[59]  C. Abbott,et al.  Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? , 2009, Trends in pharmacological sciences.

[60]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[61]  R. DeFronzo,et al.  Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study , 2008, Current medical research and opinion.

[62]  L. Macconell,et al.  Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Clinical therapeutics.

[63]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[64]  W. Zeng,et al.  Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. , 2006, Clinical therapeutics.